Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1419 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 12001.165 | 0.2545 | -0.8426 | 0.5382 | |
| HCC1419 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 12001.165 | 0.0096 | -0.9997 | 0.5382 | |
| HCC1428 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 11936.158 | 0.9620 | 0.8981 | 0.7417 | |
| HCC1428 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 11936.158 | 0.9468 | 0.8579 | 0.7417 | |
| HCC1428 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 11936.158 | 0.9794 | 0.9446 | 0.7417 | |
| HCC1428 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 11936.158 | 0.9477 | 0.8602 | 0.7417 | |
| HCC1428 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 11936.158 | 0.9354 | 0.8278 | 0.7417 | |
| HCC1428 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 11936.158 | 0.9550 | 0.8797 | 0.7417 | |
| HCC1428 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 11936.158 | 0.6982 | 0.2322 | 0.7417 | |
| HCC1428 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 11936.158 | 0.1534 | -0.8403 | 0.7417 | |
| HCC1428 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 11936.158 | 0.0101 | -0.9959 | 0.7417 | |
| HCC1569 | HER2amp | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 12523.165 | 0.9907 | 0.9818 | 1.0249 | |
| HCC1569 | HER2amp | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 12523.165 | 0.9635 | 0.9288 | 1.0249 | |
| HCC1569 | HER2amp | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 12523.165 | 0.9500 | 0.9023 | 1.0249 | |
| HCC1569 | HER2amp | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 12523.165 | 0.9261 | 0.8557 | 1.0249 | |
| HCC1569 | HER2amp | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 12523.165 | 0.7270 | 0.4653 | 1.0249 | |
| HCC1569 | HER2amp | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 12523.165 | 0.6050 | 0.2249 | 1.0249 | |
| HCC1569 | HER2amp | Basal A | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 12523.165 | 0.5942 | 0.2035 | 1.0249 | |
| HCC1569 | HER2amp | Basal A | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 12523.165 | 0.4840 | -0.0147 | 1.0249 | |
| HCC1569 | HER2amp | Basal A | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 12523.165 | 0.0204 | -0.9551 | 1.0249 | |
| HCC1806 | TNBC | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 12239.165 | 0.9916 | 0.9918 | 2.0705 | |
| HCC1806 | TNBC | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 12239.165 | 0.9694 | 0.9702 | 2.0705 | |
| HCC1806 | TNBC | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 12239.165 | 0.9452 | 0.9463 | 2.0705 | |
| HCC1806 | TNBC | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 12239.165 | 0.7911 | 0.7860 | 2.0705 | |
| HCC1806 | TNBC | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 12239.165 | 0.7063 | 0.6908 | 2.0705 |